$20.40
2.49% yesterday
Nasdaq, Jun 12, 10:00 pm CET
ISIN
US64049K1043
Symbol
NGNE
Sector
Industry

Neoleukin Therapeutics Inc Stock price

$20.40
+2.70 15.25% 1M
-1.94 8.66% 6M
-2.46 10.76% YTD
-16.78 45.13% 1Y
-235.60 92.03% 5Y
-129.40 86.38% 10Y
-218.60 91.46% 20Y
Nasdaq, Closing price Thu, Jun 12 2025
-0.52 2.49%
ISIN
US64049K1043
Symbol
NGNE
Sector
Industry

Key metrics

Market capitalization $290.95m
Enterprise Value $-1.59m
EV/FCF (TTM) EV/FCF 0.02
P/B ratio (TTM) P/B ratio 1.04
Free Cash Flow (TTM) Free Cash Flow $-71.25m
Cash position $292.60m
P/E forward negative
Short interest 21.30%

Is Neoleukin Therapeutics Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,845 stocks worldwide.

Neoleukin Therapeutics Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

7 Analysts have issued a Neoleukin Therapeutics Inc forecast:

6x Buy
86%
1x Hold
14%

Analyst Opinions

7 Analysts have issued a Neoleukin Therapeutics Inc forecast:

Buy
86%
Hold
14%

Financial data from Neoleukin Therapeutics Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
0.93 0.93
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 23 23
104% 104%
2,431%
- Research and Development Expense 61 61
36% 36%
6,540%
-79 -79
62% 62%
-8,528%
- Depreciation and Amortization 3.20 3.20
2% 2%
344%
EBIT (Operating Income) EBIT -83 -83
58% 58%
-8,872%
Net Profit -75 -75
107% 107%
-8,080%

In millions USD.

Don't miss a Thing! We will send you all news about Neoleukin Therapeutics Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Neoleukin Therapeutics Inc Stock News

Neutral
Business Wire
7 days ago
NEW YORK--(BUSINESS WIRE)--Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced that the Compensation Committee of the Company's Board of Directors approved the grant of non-qualified stock options to purchase an aggregate of 39,345 shares of the Company's common ...
Neutral
Business Wire
28 days ago
NEW YORK--(BUSINESS WIRE)--Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced an oral presentation at the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting describing a monitoring and treatment algorithm intended to reverse the rare, severe hyperi...
Neutral
Business Wire
about one month ago
NEW YORK--(BUSINESS WIRE)--Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced first quarter 2025 financial results and highlighted recent corporate updates. “We have made significant progress in planning for our future registrational trial with NGN-401 gene ther...
More Neoleukin Therapeutics Inc News

Company Profile

Neoleukin Therapeutics, Inc. operates as a biopharmaceutical company, which computational methods to design de novo protein therapeutics. The firm address significant medical needs in oncology, inflammation, and autoimmunity. Its lead product candidate, NL-201, is a combined IL-2 and IL-15 agonist designed to eliminate alpha receptor binding. The company was founded by Daniel-Adriano Silva, Carl Walkey, and Umut Ulge in December 2003 and is headquartered in Seattle, WA.

Head office United States
CEO Rachel McMinn
Employees 107
Founded 2018
Website www.neurogene.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today